The Tufts Center for the Study of Drug Development is gathering new benchmark data on the vendor qualification process including the time, cost, and resources required to qualify contract service and technology vendors.
The Tufts Center for the Study of Drug Development (Tufts CSDD) is conducting an important new empirical study looking at the time and cost of the vendor qualification assessment process to all stakeholders involved—including those who issue RFIs/RFPs and conduct qualifications and those who respond to them. Tufts CSDD is hoping to gather a large robust global response. To complete a survey, please choose the appropriate questionnaire:
All responses are confidential and will only be presented in the aggregate - no individual or organization will be identified.
Tufts CSDD will send you a summary report of the results as a thank you for your participation.
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
The Rise of Predictive Engagement Tools in Clinical Trials
November 22nd 2024Patient attrition can be a significant barrier to the success of a randomized controlled trial (RCT). Today, with the help of AI-powered predictive engagement tools, clinical study managers are finding ways to proactively reduce attrition rates in RCTs, and increase the effectiveness of their trial. In this guide, we look at the role AI-powered patient engagement tools play in clinical research, from the problems they’re being used to solve to the areas and indications in which they’re being deployed.